Covered recipient · General Payments record
JAMES LLOYD WADE
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$4,185.31
134 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,685.31 | 133 |
| Consulting Fee | $1,500.00 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES LLOYD WADE
NPI 1992774459 · CMS profile ID 44908
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
DECATUR, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992774459?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES LLOYD WADE, NPI 1992774459, CMS profile ID 44908. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992774459?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JAMES LLOYD WADE, NPI 1992774459, CMS profile ID 44908. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992774459?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JAMES LLOYD WADE, NPI 1992774459, CMS profile ID 44908, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1992774459?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
134 matching records · $4,185.31 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–134 of 134.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $23.46 | 03/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045442897 | CMS |
| Celgene Corporation | $15.48 | 03/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016197205 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $33.82 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998297457 | CMS |
| Gilead Sciences, Inc. | $18.11 | 03/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025889027 | CMS |
| Karyopharm Therapeutics Inc. | $20.09 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056901965 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.69 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997065343 | CMS |
| Stemline Therapeutics Inc. | $20.64 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040027803 | CMS |
| Lilly USA, LLC | $20.18 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031601985 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.30 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011590349 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.40 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011580959 | CMS |
| Novartis Pharmaceuticals Corporation | $26.60 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993363277 | CMS |
| Merck Sharp & Dohme LLC | $14.67 | 02/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048557801 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.93 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015753361 | CMS |
| Novartis Pharmaceuticals Corporation | $13.71 | 02/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993363275 | CMS |
| G1 Therapeutics, Inc. | $17.93 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059919125 | CMS |
| Novartis Pharmaceuticals Corporation | $24.83 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993363273 | CMS |
| AbbVie Inc. | $30.77 | 02/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999464173 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.02 | 02/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015273969 | CMS |
| Celgene Corporation | $17.91 | 02/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016197145 | CMS |
| SOBI, INC | $23.00 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038073599 | CMS |
| GlaxoSmithKline, LLC. | $17.02 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002944279 | CMS |
| GENZYME CORPORATION | $20.66 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049623609 | CMS |
| Lilly USA, LLC | $18.24 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031542657 | CMS |
| Lilly USA, LLC | $0.60 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031607083 | CMS |
| AVEO Pharmaceuticals, Inc. | $18.63 | 01/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049060015 | CMS |
| Daiichi Sankyo Inc. | $20.12 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006372035 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $30.97 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998297455 | CMS |
| Genentech USA, Inc. | $19.99 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040386047 | CMS |
| Novartis Pharmaceuticals Corporation | $13.09 | 01/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993363271 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.67 | 01/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011570227 | CMS |
| Mirati Therapeutics, Inc. | $14.11 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1058005887 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.33 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011500077 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.59 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014224061 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.03 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011988475 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $508,074.52 | 87 |
| PY2024 | Principal investigator | $70,508.04 | 33 |
| PY2023 | Principal investigator | $448,790.19 | 58 |
| PY2022 | Principal investigator | $264,960.61 | 54 |
| PY2021 | Principal investigator | $496,920.45 | 39 |
| PY2020 | Principal investigator | $251,088.15 | 56 |
| PY2019 | Recipient | $26.40 | 1 |
| PY2019 | Principal investigator | $621,621.65 | 44 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
87 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $7,968.73 | 12/27/2025 | Non-covered Recipient Entity CANCER CARE SPECIALISTS OF ILLINOIS | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228732141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,296.00 | 12/26/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175428596 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 12/22/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175428734 |
| Principal investigator 1 | BioNTech SE | $688.50 | 12/19/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249013073 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/11/2025 | Non-covered Recipient Entity Cancer Care Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228714122 |
| Principal investigator 1 | BioNTech SE | $688.50 | 12/04/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249013069 |
| Principal investigator 1 | BioNTech SE | $15.60 | 12/01/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT122 | No dispute reported | 06/30/2026 | 1249013079 |
| Principal investigator 1 | PFIZER INC. | $520.00 | 11/24/2025 | Covered Recipient Teaching Hospital DECATUR MEMORIAL HOSPITAL | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228727445 |
| Principal investigator 1 | BioNTech SE | $1,377.00 | 11/20/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249013085 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298920 |
| Principal investigator 1 | PFIZER INC. | $10,687.02 | 11/14/2025 | Non-covered Recipient Entity CANCER CARE SPECIALISTS OF ILLINOIS | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228729243 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $750.00 | 11/12/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190329223 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,334.00 | 11/07/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175428193 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,618.00 | 11/05/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lung04 | No dispute reported | 06/30/2026 | 1185543352 |
| Principal investigator 1 | PFIZER INC. | $1,750.00 | 11/04/2025 | Non-covered Recipient Entity Exigent Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228729494 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.75 | 11/03/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Central Illinois | DS1062-328 | No dispute reported | 06/30/2026 | 1223365273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $94.00 | 11/03/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Central Illinois | DS1062-328 | No dispute reported | 06/30/2026 | 1223365275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $376.00 | 11/03/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Central Illinois | DS1062-328 | No dispute reported | 06/30/2026 | 1223365277 |
| Principal investigator 1 | BioNTech SE | $15.60 | 11/01/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT122 | No dispute reported | 06/30/2026 | 1249013077 |
| Principal investigator 1 | BioNTech SE | $688.50 | 10/09/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249013071 |
| Principal investigator 1 | PFIZER INC. | $520.00 | 10/06/2025 | Covered Recipient Teaching Hospital DECATUR MEMORIAL HOSPITAL | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228722662 |
| Principal investigator 1 | BioNTech SE | $15.60 | 10/01/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT122 | No dispute reported | 06/30/2026 | 1249013075 |
| Principal investigator 1 | PFIZER INC. | $67,584.75 | 09/29/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISIANA ATLAFAYETTE | Not supplied | No dispute reported | 06/30/2026 | 1228758299 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $900.00 | 09/19/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185543354 |
| Principal investigator 1 | PFIZER INC. | $27,036.00 | 09/09/2025 | Non-covered Recipient Entity Exigent Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228770785 |
| Principal investigator 1 | BioNTech SE | $15.60 | 09/01/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur | BNT122-01 | No dispute reported | 06/30/2026 | 1249017352 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $39,086.28 | 08/20/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer | No dispute reported | 06/30/2026 | 1185543350 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $24,450.00 | 08/14/2025 | Covered Recipient Teaching Hospital Springfield Memorial Hospital | A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment | No dispute reported | 06/30/2026 | 1236000248 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,150.00 | 08/12/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190329219 |
| Principal investigator 1 | BioNTech SE | $15.60 | 08/01/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur | BNT122-01 | No dispute reported | 06/30/2026 | 1249017350 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298521 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298538 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298743 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298819 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298881 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298999 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299031 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299171 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299250 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 08/01/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299393 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $750.00 | 07/15/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190329221 |
| Principal investigator 1 | BioNTech SE | $15.60 | 07/01/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur | BNT122-01 | No dispute reported | 06/30/2026 | 1249017348 |
| Principal investigator 1 | BioNTech SE | $925.00 | 06/24/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012915 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,460.25 | 06/24/2025 | Non-covered Recipient Entity Decatur Memorial Hospital | A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment | No dispute reported | 06/30/2026 | 1235997748 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,460.02 | 06/24/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Illinois | A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment | No dispute reported | 06/30/2026 | 1235998432 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 06/23/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298901 |
| Principal investigator 1 | BioNTech SE | $600.00 | 06/19/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT-122-01 | No dispute reported | 06/30/2026 | 1249012917 |
| Principal investigator 1 | BioNTech SE | $1,377.00 | 06/12/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012925 |
| Principal investigator 1 | Celgene Corporation | $22,000.00 | 06/04/2025 | Non-covered Recipient Entity Exigent Research Llc | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222307011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $274.00 | 06/04/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298945 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $124,870.42 | 05/30/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185543346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298639 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,000.00 | 05/27/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175428389 |
| Principal investigator 1 | BioNTech SE | $688.50 | 05/15/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012923 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 04/30/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298490 |
| Principal investigator 1 | BioNTech SE | $1,377.00 | 04/28/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298431 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298814 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299006 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299119 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299236 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299431 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299469 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299597 |
| Principal investigator 1 | BioNTech SE | $1,377.00 | 04/23/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,000.00 | 04/15/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175428489 |
| Principal investigator 1 | PFIZER INC. | $520.00 | 04/14/2025 | Covered Recipient Teaching Hospital DECATUR MEMORIAL HOSPITAL | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228780589 |
| Principal investigator 1 | BioNTech SE | $1,377.00 | 03/19/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012913 |
| Principal investigator 1 | BioNTech SE | $688.50 | 03/04/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012911 |
| Principal investigator 1 | BioNTech SE | $688.50 | 02/25/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012909 |
| Principal investigator 1 | PFIZER INC. | $520.00 | 02/03/2025 | Covered Recipient Teaching Hospital DECATUR MEMORIAL HOSPITAL | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228793128 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,336.61 | 01/29/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | No dispute reported | 06/30/2026 | 1185543348 |
| Principal investigator 1 | BioNTech SE | $688.50 | 01/21/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012907 |
| Principal investigator 1 | BioNTech SE | $688.50 | 01/17/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012905 |
| Principal investigator 1 | BioNTech SE | $688.50 | 01/07/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012901 |
| Principal investigator 1 | BioNTech SE | $1,377.00 | 01/07/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | BNT000-001 | No dispute reported | 06/30/2026 | 1249012903 |